A randomized trial of progesterone in women with recurrent miscarriages

A. Coomarasamy, H. Williams, E. Truchanowicz, P. T. Seed, R. Small, S. Quenby, P. Gupta, F. Dawood, Y. E M Koot, R. Bender Atik, K. W M Bloemenkamp, R. Brady, A. L. Briley, R. Cavallaro, Y. C. Cheong, J. J. Chu, A. Eapen, A. Ewies, A. Hoek, E. M. Kaaijk & 15 others C. A M Koks, T. C. Li, M. MacLean, B. W. Mol, J. Moore, J. A. Ross, L. Sharpe, J. Stewart, N. Vaithilingam, R. G. Farquharson, M. D. Kilby, Y. Khalaf, M. Goddijn, L. Regan, R. Rai

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

BACKGROUND Progesterone is essential for the maintenance of pregnancy. However, whether progesterone supplementation in the first trimester of pregnancy would increase the rate of live births among women with a history of unexplained recurrent miscarriages is uncertain. METHODS We conducted a multicenter, double-blind, placebo-controlled, randomized trial to investigate whether treatment with progesterone would increase the rates of live births and newborn survival among women with unexplained recurrent miscarriage. We randomly assigned women with recurrent miscarriages to receive twicedaily vaginal suppositories containing either 400 mg of micronized progesterone or matched placebo from a time soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) through 12 weeks of gestation. The primary outcome was live birth after 24 weeks of gestation. RESULTS A total of 1568 women were assessed for eligibility, and 836 of these women who conceived naturally within 1 year and remained willing to participate in the trial were randomly assigned to receive either progesterone (404 women) or placebo (432 women). The follow-up rate for the primary outcome was 98.8% (826 of 836 women). In an intention-to-treat analysis, the rate of live births was 65.8% (262 of 398 women) in the progesterone group and 63.3% (271 of 428 women) in the placebo group (relative rate, 1.04; 95% confidence interval [CI], 0.94 to 1.15; rate difference, 2.5 percentage points; 95% CI, -4.0 to 9.0). There were no significant between-group differences in the rate of adverse events. CONCLUSIONS Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with a history of unexplained recurrent miscarriages.

LanguageEnglish
Pages2141-2148
Number of pages8
JournalNew England Journal of Medicine
Volume373
Issue number22
DOIs
Publication statusPublished - 26 Nov 2015

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Coomarasamy, A., Williams, H., Truchanowicz, E., Seed, P. T., Small, R., Quenby, S., ... Rai, R. (2015). A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine, 373(22), 2141-2148. https://doi.org/10.1056/NEJMoa1504927
Coomarasamy, A. ; Williams, H. ; Truchanowicz, E. ; Seed, P. T. ; Small, R. ; Quenby, S. ; Gupta, P. ; Dawood, F. ; Koot, Y. E M ; Bender Atik, R. ; Bloemenkamp, K. W M ; Brady, R. ; Briley, A. L. ; Cavallaro, R. ; Cheong, Y. C. ; Chu, J. J. ; Eapen, A. ; Ewies, A. ; Hoek, A. ; Kaaijk, E. M. ; Koks, C. A M ; Li, T. C. ; MacLean, M. ; Mol, B. W. ; Moore, J. ; Ross, J. A. ; Sharpe, L. ; Stewart, J. ; Vaithilingam, N. ; Farquharson, R. G. ; Kilby, M. D. ; Khalaf, Y. ; Goddijn, M. ; Regan, L. ; Rai, R. / A randomized trial of progesterone in women with recurrent miscarriages. In: New England Journal of Medicine. 2015 ; Vol. 373, No. 22. pp. 2141-2148.
@article{d222b6ff966c460d80a1fa7f3f5a7fe0,
title = "A randomized trial of progesterone in women with recurrent miscarriages",
abstract = "BACKGROUND Progesterone is essential for the maintenance of pregnancy. However, whether progesterone supplementation in the first trimester of pregnancy would increase the rate of live births among women with a history of unexplained recurrent miscarriages is uncertain. METHODS We conducted a multicenter, double-blind, placebo-controlled, randomized trial to investigate whether treatment with progesterone would increase the rates of live births and newborn survival among women with unexplained recurrent miscarriage. We randomly assigned women with recurrent miscarriages to receive twicedaily vaginal suppositories containing either 400 mg of micronized progesterone or matched placebo from a time soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) through 12 weeks of gestation. The primary outcome was live birth after 24 weeks of gestation. RESULTS A total of 1568 women were assessed for eligibility, and 836 of these women who conceived naturally within 1 year and remained willing to participate in the trial were randomly assigned to receive either progesterone (404 women) or placebo (432 women). The follow-up rate for the primary outcome was 98.8{\%} (826 of 836 women). In an intention-to-treat analysis, the rate of live births was 65.8{\%} (262 of 398 women) in the progesterone group and 63.3{\%} (271 of 428 women) in the placebo group (relative rate, 1.04; 95{\%} confidence interval [CI], 0.94 to 1.15; rate difference, 2.5 percentage points; 95{\%} CI, -4.0 to 9.0). There were no significant between-group differences in the rate of adverse events. CONCLUSIONS Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with a history of unexplained recurrent miscarriages.",
author = "A. Coomarasamy and H. Williams and E. Truchanowicz and Seed, {P. T.} and R. Small and S. Quenby and P. Gupta and F. Dawood and Koot, {Y. E M} and {Bender Atik}, R. and Bloemenkamp, {K. W M} and R. Brady and Briley, {A. L.} and R. Cavallaro and Cheong, {Y. C.} and Chu, {J. J.} and A. Eapen and A. Ewies and A. Hoek and Kaaijk, {E. M.} and Koks, {C. A M} and Li, {T. C.} and M. MacLean and Mol, {B. W.} and J. Moore and Ross, {J. A.} and L. Sharpe and J. Stewart and N. Vaithilingam and Farquharson, {R. G.} and Kilby, {M. D.} and Y. Khalaf and M. Goddijn and L. Regan and R. Rai",
year = "2015",
month = "11",
day = "26",
doi = "10.1056/NEJMoa1504927",
language = "English",
volume = "373",
pages = "2141--2148",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

Coomarasamy, A, Williams, H, Truchanowicz, E, Seed, PT, Small, R, Quenby, S, Gupta, P, Dawood, F, Koot, YEM, Bender Atik, R, Bloemenkamp, KWM, Brady, R, Briley, AL, Cavallaro, R, Cheong, YC, Chu, JJ, Eapen, A, Ewies, A, Hoek, A, Kaaijk, EM, Koks, CAM, Li, TC, MacLean, M, Mol, BW, Moore, J, Ross, JA, Sharpe, L, Stewart, J, Vaithilingam, N, Farquharson, RG, Kilby, MD, Khalaf, Y, Goddijn, M, Regan, L & Rai, R 2015, 'A randomized trial of progesterone in women with recurrent miscarriages', New England Journal of Medicine, vol. 373, no. 22, pp. 2141-2148. https://doi.org/10.1056/NEJMoa1504927

A randomized trial of progesterone in women with recurrent miscarriages. / Coomarasamy, A.; Williams, H.; Truchanowicz, E.; Seed, P. T.; Small, R.; Quenby, S.; Gupta, P.; Dawood, F.; Koot, Y. E M; Bender Atik, R.; Bloemenkamp, K. W M; Brady, R.; Briley, A. L.; Cavallaro, R.; Cheong, Y. C.; Chu, J. J.; Eapen, A.; Ewies, A.; Hoek, A.; Kaaijk, E. M.; Koks, C. A M; Li, T. C.; MacLean, M.; Mol, B. W.; Moore, J.; Ross, J. A.; Sharpe, L.; Stewart, J.; Vaithilingam, N.; Farquharson, R. G.; Kilby, M. D.; Khalaf, Y.; Goddijn, M.; Regan, L.; Rai, R.

In: New England Journal of Medicine, Vol. 373, No. 22, 26.11.2015, p. 2141-2148.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A randomized trial of progesterone in women with recurrent miscarriages

AU - Coomarasamy, A.

AU - Williams, H.

AU - Truchanowicz, E.

AU - Seed, P. T.

AU - Small, R.

AU - Quenby, S.

AU - Gupta, P.

AU - Dawood, F.

AU - Koot, Y. E M

AU - Bender Atik, R.

AU - Bloemenkamp, K. W M

AU - Brady, R.

AU - Briley, A. L.

AU - Cavallaro, R.

AU - Cheong, Y. C.

AU - Chu, J. J.

AU - Eapen, A.

AU - Ewies, A.

AU - Hoek, A.

AU - Kaaijk, E. M.

AU - Koks, C. A M

AU - Li, T. C.

AU - MacLean, M.

AU - Mol, B. W.

AU - Moore, J.

AU - Ross, J. A.

AU - Sharpe, L.

AU - Stewart, J.

AU - Vaithilingam, N.

AU - Farquharson, R. G.

AU - Kilby, M. D.

AU - Khalaf, Y.

AU - Goddijn, M.

AU - Regan, L.

AU - Rai, R.

PY - 2015/11/26

Y1 - 2015/11/26

N2 - BACKGROUND Progesterone is essential for the maintenance of pregnancy. However, whether progesterone supplementation in the first trimester of pregnancy would increase the rate of live births among women with a history of unexplained recurrent miscarriages is uncertain. METHODS We conducted a multicenter, double-blind, placebo-controlled, randomized trial to investigate whether treatment with progesterone would increase the rates of live births and newborn survival among women with unexplained recurrent miscarriage. We randomly assigned women with recurrent miscarriages to receive twicedaily vaginal suppositories containing either 400 mg of micronized progesterone or matched placebo from a time soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) through 12 weeks of gestation. The primary outcome was live birth after 24 weeks of gestation. RESULTS A total of 1568 women were assessed for eligibility, and 836 of these women who conceived naturally within 1 year and remained willing to participate in the trial were randomly assigned to receive either progesterone (404 women) or placebo (432 women). The follow-up rate for the primary outcome was 98.8% (826 of 836 women). In an intention-to-treat analysis, the rate of live births was 65.8% (262 of 398 women) in the progesterone group and 63.3% (271 of 428 women) in the placebo group (relative rate, 1.04; 95% confidence interval [CI], 0.94 to 1.15; rate difference, 2.5 percentage points; 95% CI, -4.0 to 9.0). There were no significant between-group differences in the rate of adverse events. CONCLUSIONS Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with a history of unexplained recurrent miscarriages.

AB - BACKGROUND Progesterone is essential for the maintenance of pregnancy. However, whether progesterone supplementation in the first trimester of pregnancy would increase the rate of live births among women with a history of unexplained recurrent miscarriages is uncertain. METHODS We conducted a multicenter, double-blind, placebo-controlled, randomized trial to investigate whether treatment with progesterone would increase the rates of live births and newborn survival among women with unexplained recurrent miscarriage. We randomly assigned women with recurrent miscarriages to receive twicedaily vaginal suppositories containing either 400 mg of micronized progesterone or matched placebo from a time soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) through 12 weeks of gestation. The primary outcome was live birth after 24 weeks of gestation. RESULTS A total of 1568 women were assessed for eligibility, and 836 of these women who conceived naturally within 1 year and remained willing to participate in the trial were randomly assigned to receive either progesterone (404 women) or placebo (432 women). The follow-up rate for the primary outcome was 98.8% (826 of 836 women). In an intention-to-treat analysis, the rate of live births was 65.8% (262 of 398 women) in the progesterone group and 63.3% (271 of 428 women) in the placebo group (relative rate, 1.04; 95% confidence interval [CI], 0.94 to 1.15; rate difference, 2.5 percentage points; 95% CI, -4.0 to 9.0). There were no significant between-group differences in the rate of adverse events. CONCLUSIONS Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with a history of unexplained recurrent miscarriages.

UR - http://www.scopus.com/inward/record.url?scp=84948399630&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1504927

DO - 10.1056/NEJMoa1504927

M3 - Article

VL - 373

SP - 2141

EP - 2148

JO - New England Journal of Medicine

T2 - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -

Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S et al. A randomized trial of progesterone in women with recurrent miscarriages. New England Journal of Medicine. 2015 Nov 26;373(22):2141-2148. https://doi.org/10.1056/NEJMoa1504927